Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (NYSE:DGX) released its 2025 Drug Testing Index, revealing concerning trends in workplace drug testing. The analysis of over 8 million drug tests shows that fentanyl positivity in random tests (1.13%) was 707% higher than in pre-employment tests (0.14%), suggesting increased on-the-job usage.

While overall workplace drug positivity slightly declined to 4.4% from 4.6%, the data showed that 60% of fentanyl-positive specimens also contained other drugs. Notably, marijuana co-positivity with fentanyl doubled since 2020 to 22%, while amphetamine co-positivity increased to 16% from 11%.

The report also highlighted that marijuana remains the most detected substance with 4.5% positivity in the general workforce, with concerning post-accident positivity rates of 7.3%. For-cause testing showed a 33.1% positivity rate, demonstrating ongoing workplace substance abuse challenges.

Quest Diagnostics (NYSE:DGX) and Corewell Health have announced a strategic joint venture to form Diagnostic Lab of Michigan, LLC. The partnership includes building a 100,000-square-foot state-of-the-art laboratory in Southfield, Michigan, featuring advanced technologies for automated microbiology and high-throughput molecular testing.

Under the agreement, Quest will hold 51% ownership while Corewell Health will retain 49%. Quest will manage Corewell Health's 21 hospital laboratories across Michigan through its Collaborative Lab Solutions program. The joint venture transaction is expected to complete in Q1 2026, with the new laboratory becoming operational in Q1 2027.

Quest Diagnostics (NYSE:DGX) has received FDA Breakthrough Device Designation for its Haystack MRD® test, designed to identify minimal residual disease (MRD) in stage II colorectal cancer patients after surgery. The test helps determine which patients might benefit from adjuvant therapy.

The designation follows Quest's launch of a clinical laboratory-developed version of Haystack MRD in late 2024. The test utilizes circulating tumor DNA (ctDNA) technology to detect residual or recurrent cancer from solid tumors. The Breakthrough Device Program aims to accelerate development and review of medical devices for life-threatening conditions while maintaining FDA safety standards.

Quest Diagnostics (NYSE: DGX), a diagnostic information services leader, has announced that Chairman, CEO and President Jim Davis will participate in the Baird 2025 Global Healthcare Conference. The presentation will take place on September 10, 2025, at 10:50 a.m. Eastern Time in New York City.

The event will feature a fireside chat and Q&A session focusing on Quest's strategy, performance, and market trends. Investors can access the live webcast through Quest's investor relations website at ir.QuestDiagnostics.com. The archived webcast will be available within 24 hours after the event and remain accessible until October 3, 2025.

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has announced a quarterly cash dividend. The company's Board of Directors has declared a dividend of $0.80 per share. The dividend will be paid on October 20, 2025, to shareholders who hold Quest Diagnostics common stock as of the record date of October 3, 2025.

Quest Diagnostics (NYSE:DGX) subsidiary Haystack Oncology announced a research collaboration with Mass General Brigham to conduct two clinical trials studying Haystack MRD™, a ctDNA minimal residual disease test. The trials will investigate the test's effectiveness in guiding post-surgical treatment decisions for cutaneous squamous cell carcinoma (CSCC) and HPV-independent head and neck squamous cell carcinoma (HNSCC).

The studies will analyze patient samples at multiple timepoints to evaluate Haystack MRD's clinical utility. A recent NEJM study showed the test could identify clinical complete response at 1.4 months compared to over six months using imaging tests. According to a Harris Poll, 96% of oncologists believe MRD testing can detect cancer recurrence earlier than traditional methods.

Quest Diagnostics (NYSE: DGX) has completed its acquisition of select clinical testing assets from Spectra Laboratories, owned by Fresenius Medical Care. The deal positions Quest to provide dialysis-related clinical testing to independent dialysis clinics previously served by Spectra.

Under a separate laboratory services agreement, Quest will begin providing comprehensive dialysis-related laboratory services for Fresenius Medical Care's U.S. dialysis centers, serving approximately 200,000 patients annually. The service transition will start this month and is expected to complete by early 2026.

The strategic acquisition will leverage Quest's laboratory network to reduce transportation time and expedite results reporting. Quest plans to optimize capital returns by utilizing its facilities during lower-volume daytime hours.

Quest Diagnostics (NYSE: DGX) subsidiary Athena Diagnostics has launched a new laboratory test service for improved genetic testing of ataxia, a group of degenerative neurological disorders affecting movement and coordination. The test, developed in collaboration with PacBio (NASDAQ: PACB), utilizes PacBio's PureTarget sequencing method to identify long DNA repeat sequences that conventional testing might miss.

The new test will serve as a confirmatory tool following initial PCR screening, with testing conducted at Athena's Marlborough laboratory. A preprint study demonstrated the test's ability to identify specific gene patterns in Spinocerebellar ataxia type 10, potentially helping predict disease onset. Recent studies indicate ataxia affects 26 per 100,000 children, with genetic causes accounting for 10 per 100,000 cases.

Quest Diagnostics (NYSE:DGX) reported strong Q2 2025 financial results, with revenues reaching $2.76 billion, up 15.2% year-over-year. The company's reported diluted EPS increased 21.7% to $2.47, while adjusted diluted EPS grew 11.5% to $2.62.

Key performance metrics include a 16.3% increase in requisition volume, with organic requisition volume up 2.1%. Operating income rose 23.3% to $438 million, and cash from operations surged 67.1% to $858 million year-to-date.

Following these strong results, Quest has raised its full-year 2025 guidance, now expecting net revenues between $10.80-10.92 billion and adjusted diluted EPS of $9.63-9.83. The company attributes its performance to innovative clinical solutions, expanded enterprise accounts, and operational efficiency gains through automation and digital technologies.